Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2014 Jun;10(6):705-11. doi: 10.1586/1744666X.2014.910119. Epub 2014 May 2.

Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.

Author information

1
Department of Oncology, KU Leuven, Laboratory of Pediatric Immunology, Onderwijs and Navorsing 1, Herestraat 49, box 811, 3000 Leuven, Belgium.

Abstract

Pelvic gynecological malignancies account for 6% of all cancers. In the relapsed state, classical treatments are limited. There is an urgent need for new and personalized treatment. Wilms' tumor gene 1 (WT1) is the most important tumor-associated antigen. Although highly present in gynecological tumors, active immunotherapy against it is still underexplored. This review gives an insight into the importance of WT1 in pelvic gynecological malignancies and the first taken steps into the world of WT1 immunotherapy.

KEYWORDS:

DC; WT1; Wilms' tumor gene 1; dendritic cell; immunotherapy; ovarian cancer; uterine cancer

PMID:
24784346
DOI:
10.1586/1744666X.2014.910119
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center